Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma

Al-Batran, S-e., Wainberg, Z. A., Muro, K., Molena, D., Van Cutsem, E., Hyung, W. J., Wyrwicz, L. S., Moehler, M., Herrero, F. Rivera, Oh, D-y., Omori, T., Smyth, E. C., Liberman, M., Stein, A., Bilici, M., Serrano, O., Heilbron, E., Hernandorena, F., Tabernero, J., Janjigian, Y. Y.